FOXM1 and liver cancer: Altogether, these results, strongly confirm that knock-out of IQGAP1/FOXM1 with sgIF loaded HLC9-EVs + sorafenib in effect reduces CD133+ CSCs and reverses sorafenib resistance, and hence stands as promising novel therapeutic approach for thriving liver cancer treatments in the future.